Association of Type 2 diabetes remission with mortality and vascular outcomes: a systematic review and meta-analysis of longitudinal studies

Q: What are the key findings of this study?

Type 2 diabetes mellitus remission was associated with a 32% lower hazard of cardiovascular events (HR 0.68, 95% CI 0.59-0.80, P=0.003) compared with not achieving remission.

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Type 2 diabetes mellitus. Intervention: Type 2 diabetes mellitus remission vs. Did not achieve or maintain diabetes remission. Primary outcome: Cardiovascular events (HR 0.68, 95% CI 0.59-0.80, p=0.003).

Q: What does this research mean for the field?

Type 2 diabetes mellitus remission is associated with a 32% lower hazard of cardiovascular events compared with not achieving remission. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Hao Bai; Lingqiao Song; Yating Zhan; Li Dai; Qian He; Jiaxin Duan; Haiyan Yang; Li Liao; Rong Huang

doi:10.1186/s13098-026-02314-w

October 22, 2026Diabetology & Metabolic SyndromeOpen Access

Association of Type 2 diabetes remission with mortality and vascular outcomes: a systematic review and meta-analysis of longitudinal studies

View Full Paper

Ask AI

Bookmark

Share

Key result

Type 2 diabetes remission is linked to ~32% lower risk of cardiovascular events.

HR 0.68
95% CI 0.59-0.80
P=0.003

Why the study?

Although T2DM remission is increasingly recognized as an achievable clinical state, its long-term associations with mortality and vascular complications remained uncertain.

Is type 2 diabetes mellitus remission associated with lower hazards of all-cause mortality, cardiovascular events, and microvascular or macrovascular complications in adults with type 2 diabetes?

Key Points

To assess the long-term associations of type 2 diabetes mellitus (T2DM) remission with all-cause mortality, cardiovascular events, microvascular complications, and macrovascular complications.
Searched PubMed, Embase, Web of Science, and Scopus from inception through July 20, 2026, without language restrictions.
Included longitudinal studies of adults with T2DM assessing remission before outcome ascertainment, comparing remission achievers to non-achievers with at least 12 months of follow-up.
Extracted adjusted hazard ratios (HRs) and pooled them using random-effects models across 10 eligible studies (9 in quantitative synthesis; median sample size 9,412; follow-up 4.0 to 32.2 years).
Remission was associated with a lower hazard of cardiovascular events (5 studies, N=96,400; HR, 0.68; 95% CI, 0.59–0.80; P = 0.003; I² = 11.7%).
Pooled analyses suggested lower hazards of microvascular complications (5 studies; HR, 0.60; 95% CI, 0.38–0.93; I² = 93.4%) and macrovascular complications (6 studies; HR, 0.74; 95% CI, 0.58–0.93; I² = 75.6%), although certainty was very low due to substantial heterogeneity.

Study Design

Type

Meta-Analysis

Multicenter

Yes

Structured PICO

Is type 2 diabetes mellitus remission associated with lower hazards of all-cause mortality, cardiovascular events, and microvascular or macrovascular complications in adults with type 2 diabetes?

P

Population

Adults aged ≥18 years with type 2 diabetes mellitus across 10 longitudinal studies (median sample size 9,412; range 586–60,287; mean/median age 46.7–67.0 years; 13.4%–76.0% female) followed for 4.0 to 32.2 years after remission assessment.

E

Exposure

Achievement of type 2 diabetes mellitus remission (achieved via surgical or nonsurgical pathways; generally defined as HbA1c <6.5% in the absence of glucose-lowering medication use, assessed via single or repeated ascertainment)

C

Comparator

Participants with type 2 diabetes mellitus who did not achieve or maintain remission

O

Outcome

Co-primary outcomes evaluated across 4.0 to 32.2 years of follow-up: cardiovascular events (5 studies, n=96,400), all-cause mortality (3 studies, n=98,050), microvascular complications (renal, retinal, and neurologic outcomes; 5 studies), and macrovascular complications (coronary, cerebrovascular, peripheral arterial, and other atherosclerotic outcomes; 6 studies)hard clinical

Main Result

Hazard Ratio: 0.68 (95% CI 0.59–0.8)

p-value: p=0.003

Limitations

Dominated by observational studies, precluding causal inference and allowing residual confounding, reverse causation, and selection bias
Susceptibility to immortal-time or other time-related biases depending on how remission and follow-up start were defined
Variability in remission definitions and ascertainment schedules across studies, including single time-point assessments
Substantial clinical and methodological heterogeneity in outcome definitions, baseline populations, follow-up durations, covariate adjustments, and competing-risk handling
Small number of contributing studies per outcome, limiting precision, subgroup power, and publication bias assessment
Use of aggregate rather than individual-participant data
Observational study dominance precluding causal inference and subject to residual confounding, reverse causation, and selection bias
Potential immortal-time or other time-related biases across included studies
Heterogeneous remission definitions and ascertainment schedules across studies
Differences in outcome definitions, baseline populations, follow-up durations, covariate adjustment sets, and competing-risk handling
Few studies per outcome (3 to 6 studies), limiting precision and preventing formal publication bias assessment
Reliance on aggregate rather than individual-participant data

Implication

Type 2 diabetes remission is consistently associated with a 32% lower hazard of cardiovascular events (HR 0.68), though low-to-very-low certainty observational evidence and risk of relapse warrant continued long-term cardiometabolic surveillance.

Abstract

Type 2 diabetes mellitus (T2DM) remission is increasingly recognized as an achievable clinical state. However, its long-term associations with mortality and vascular complications remain uncertain. We conducted a systematic review and meta-analysis of longitudinal studies to evaluate the associations of T2DM remission with all-cause mortality, cardiovascular events, microvascular complications, and macrovascular complications. PubMed, Embase, Web of Science, and Scopus were searched from inception to July 20, 2026, without language restrictions. Longitudinal studies were eligible if they included adults with T2DM, assessed remission before outcome ascertainment, compared participants who achieved remission with those who did not achieve or maintain remission, and reported an adjusted effect estimate after at least 12 months of follow-up. Methodological quality was assessed using the Newcastle–Ottawa Scale. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using random-effects models. The certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Ten studies met the eligibility criteria, of which nine contributed to the quantitative synthesis. T2DM remission was not significantly associated with all-cause mortality (3 studies; HR, 0.80; 95% CI, 0.53–1.21; I² = 65.0%), but pooled estimates suggested lower hazards of cardiovascular events (5 studies; HR, 0.68; 95% CI, 0.59–0.80; I² = 11.7%) and microvascular complications (5 studies; HR, 0.60; 95% CI, 0.38–0.93; I² = 93.4%). In an exploratory analysis of broader macrovascular complications, the pooled estimate also suggested a lower hazard (6 studies; HR, 0.74; 95% CI, 0.58–0.93; I² = 75.6%), although substantial heterogeneity was observed. Sensitivity analyses did not materially alter the overall direction of the pooled estimates. The certainty of evidence was low for cardiovascular events and very low for all-cause mortality, microvascular complications, and macrovascular complications. T2DM remission was associated with lower pooled hazards of cardiovascular events, while the associations with microvascular and macrovascular complications were less certain due to substantial heterogeneity and limited precision. The association between T2DM remission and all-cause mortality remained uncertain. These findings suggest a favorable long-term prognostic association of T2DM remission, although they should not be interpreted as evidence of causality. Long-term glycemic monitoring, comprehensive risk-factor management, and surveillance for diabetes-related complications should therefore continue after remission.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bai et al. (2026) conducted a meta-analysis in Type 2 diabetes mellitus. Type 2 diabetes mellitus remission vs. Did not achieve or maintain diabetes remission was evaluated on Cardiovascular events (HR 0.68, 95% CI 0.59-0.80, p=0.003). Type 2 diabetes mellitus remission was associated with a 32% lower hazard of cardiovascular events (HR 0.68, 95% CI 0.59-0.80, P=0.003) compared with not achieving remission.

synapsesocial.com/papers/6adc4a3812ed3812d0268d77 https://doi.org/10.1186/s13098-026-02314-w

View Full Paper

Ask AI

Bookmark

Share

Association of Type 2 diabetes remission with mortality and vascular outcomes: a systematic review and meta-analysis of longitudinal studies

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Association of Type 2 diabetes remission with mortality and vascular outcomes: a systematic review and meta-analysis of longitudinal studies

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading